[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589614":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of Nottingham","OTHER",[8,12,14,16,18,20],{"label":9,"type":10,"description":11,"interventionNames":10},"Crohn's Disease - anti-TNFα therapy",null,"Consultant will prescribe biologic dose, frequency and duration as normal standard of care",{"label":13,"type":10,"description":11,"interventionNames":10},"Crohn's Disease - ustekinumab",{"label":15,"type":10,"description":11,"interventionNames":10},"Crohn's Disease - upadacitinib",{"label":17,"type":10,"description":11,"interventionNames":10},"Ulcerative Colitis - anti-TNFα therapy",{"label":19,"type":10,"description":11,"interventionNames":10},"Ulcerative Colitis - vedolizumab",{"label":21,"type":10,"description":22,"interventionNames":10},"Control non-IBD","No biologic will be prescribed",[24],{"name":25,"affiliation":5,"role":26},"Gordon Moran Professor","PRINCIPAL_INVESTIGATOR",[28,33],{"name":25,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","0115 9249924","80608","Gordon.Moran@nottingham.ac.uk",{"name":34,"role":29,"phone":10,"phoneExt":10,"email":35},"Nadia Frowd","nadia.frowd1@nhs.net",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Nottingham","Nottinghamshire","NG7 2UH","United Kingdom","UK",{"type":45,"coordinates":46},"Point",[47,48],-1.15047,52.9536,{"lat":48,"lon":47},[51],{"name":25,"role":29,"phone":10,"phoneExt":10,"email":52},"gordon.moran@nottingham.ac.uk",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[56],{"name":57,"class":6},"Nottingham University Hospitals NHS Trust","100589614","naza---nottinghamastra-zeneca-prospective-ibd-cohort-study-100589614",false,"NCT06956703","NAZA - Nottingham\u002FAstra ZenecA Prospective IBD Cohort Study","NAZA","Inclusion Criteria:\n\n1\\. Provision of signed and dated, written informed consent before any study specific procedures\n\nAND\n\n2a. Patients of at least 16 years of age with active Crohn's disease defined as: CRP \\> = 5 mg\u002FL OR FCP \\> = 250 μg\u002Fg OR Visible ulcerations on ileocolonoscopy with a total SES-CD \\> = 7, or \\> = 4 if disease is confined to the terminal ileum OR visable active disease on cross-sectional imaging. Are switching to a new mechanism of action (MOA) onto anti-TNF therapy or ustekinumab or upadacitinib\n\nOR\n\n2b. Patients of at least 16 years (no upper age limit) with active UC defined as: CRP \\> = 5 mg\u002FL OR FCP \\> = 250 μg\u002Fg OR Mayo endoscopy subscore \\> = 2. Are switching to a new mechanism of action (MOA) onto either anti-TNFα therapy or vedolizumab\n\nOR\n\n2c. Non-IBD participants who are attending for a lower GI colonoscopy at any participating site. On any hospital\u002F medical\u002F clinical screening list or any other appropriate list with no pathology found on examination.\n\nExclusion Criteria:\n\n1. Inability to give informed consent\n2. Any positive result from previous screening for serum hepatitis B surface antigen, hepatitis C or human immunodeficiency virus (HIV)\n3. An ongoing infection requiring treatment\n4. Clinical evidence of active COVID infection and\u002For evidence of active COVID determined by local standard care procedures\n5. Participation in a clinical study with pharmacological intervention within 3 months prior to Baseline visit.\n6. Current diagnosis of cancer\n7. Having received a solid organ or stem cell transplant\n8. Having received a transfusion of blood, plasma, or platelets within 120 days prior to enrolment\n9. Confirmed pregnancy at time of enrolment\n10. For non-IBD participants: A prior history of IBD (CD, UC, microscopic colitis, indeterminate colitis or IBD unspecified)\n11. Clinical judgement by the investigator that the patient should not participate in the study\n12. Under 16yrs of age",true,"ALL","16 Years",{"count":69,"type":70},240,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants.\n\nThe main question it aims to answer is:\n\nAre there differences in inflammatory markers between IBD and non-IBD (control) participants.",[74,75,76,77],"Gastro-Intestinal Disorder","Crohn Disease","Ulcerative Colitis","Inflammatory Bowel Diseases","2025-05-22",{"date":80,"type":81},"2025-05-29","ACTUAL",{"date":83,"type":81},"2022-12-12",{"date":85,"type":70},"2027-02-28",{"name":5,"class":6},1]